Citi analyst Yigal Nochomovitz would be buying the selloff in Travere Therapeutics (TVTX) on news the company received standard versus the anticipated priority review timeframe for sparsentan in focal segmental glomerulosclerosis. The firm says the four month clock to organize, prepare for and hold an advisory committee meeting and then reach an approval determination “was too tight” in light of possible workload balance/constraints at an evolving FDA. Citi believes the standard review timeline does not change conviction on the conclusions from the PARASOL working group supporting proteinurea as an approvable endpoint in FSGS. It keeps a Buy rating on Travere with a $35 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Buy Rating Reaffirmed for Travere Therapeutics Amid FDA Review and Market Overreaction
- Closing Bell Movers: Applied Materials down over 5% after Q2 results
- Travere Therapeutics’ FDA Acceptance for FILSPARI Application
- Travere Therapeutics announces FDA acceptance of sNDA for Filspari
- Travere Therapeutics: Strong Market Position and Growth Potential Drive Buy Rating